Disclaimer: This information is for educational purposes only and should not be considered medical advice. It is intended for healthcare professionals and must be used in conjunction with sound clinical judgment and patient-specific factors. Always consult official guidelines and professional medical literature for the most current and accurate information. Patient care decisions must be made by a qualified healthcare provider.

Peptic Ulcer Disease

Overview

• Definition: Peptic Ulcer Disease (PUD) is a condition characterized by a break in the gastric or duodenal mucosa that extends through the muscularis mucosae, typically due to an imbalance between aggressive (acid, pepsin, H. pylori, NSAIDs) and defensive (mucus, bicarbonate, prostaglandins, blood flow) factors. These lesions commonly occur in the stomach (gastric ulcer) or the duodenum (duodenal ulcer).
• Epidemiology:
  • Globally, the lifetime prevalence of PUD is estimated to be 5-10%.
  • The incidence of PUD has declined over the past few decades, primarily due to decreased rates of Helicobacter pylori (H. pylori) infection. However, the incidence of NSAID-induced ulcers has remained stable or slightly increased, especially among the elderly.
  • H. pylori is the most common cause, responsible for approximately 70-90% of duodenal ulcers and 50-70% of gastric ulcers.
  • NSAID use accounts for 10-20% of duodenal ulcers and 20-40% of gastric ulcers.
  • Duodenal ulcers are about four times more common than gastric ulcers and typically occur in younger patients (30-50 years), while gastric ulcers are more prevalent in older patients (50-70 years).
  • Men are slightly more affected than women.
• Classification:
  • Location:
    • Duodenal Ulcer (DU): Most common, usually in the first part of the duodenum.
    • Gastric Ulcer (GU): Most common along the lesser curvature of the stomach.
  • Etiology:
    • H. pylori-associated PUD: Ulcers caused by H. pylori infection.
    • NSAID-induced PUD: Ulcers caused by non-steroidal anti-inflammatory drug (NSAID) or aspirin (ASA) use.
    • Stress Ulcer: Acute ulcers developing in critically ill patients (e.g., sepsis, trauma, burns, head injury, mechanical ventilation); distinct from chronic PUD.
    • Zollinger-Ellison Syndrome (ZES): Rare condition causing severe PUD due to excessive gastrin production from a gastrinoma, leading to profound acid hypersecretion.
    • Other Rare Causes: Crohn's disease, viral infections (CMV, HSV), vascular insufficiency, chemotherapy, radiation, mastocytosis, specific drug use (e.g., bisphosphonates, potassium chloride).

Pathophysiology

• Mechanism: PUD results from an imbalance between aggressive factors (acid, pepsin, H. pylori, NSAIDs, bile salts) that damage the gastroduodenal mucosa and defensive factors (mucus, bicarbonate, prostaglandins, mucosal blood flow, epithelial regeneration, tight junctions) that protect it.
  • H. pylori Infection:
    • H. pylori colonizes the gastric antrum, leading to chronic inflammation (gastritis).
    • It produces urease, which hydrolyzes urea to ammonia and bicarbonate, buffering gastric acid locally and enabling survival in the acidic environment.
    • It also produces cytotoxins (e.g., VacA, CagA) and enzymes (e.g., mucinase, phospholipase) that damage mucosal cells and disrupt the protective mucus layer.
    • H. pylori infection alters gastric physiology, often leading to increased gastrin release and reduced somatostatin production, resulting in hypergastrinemia and increased acid secretion in duodenal ulcer patients. In gastric ulcer patients, H. pylori more commonly leads to pangastritis, often with gastric atrophy and reduced acid secretion, but localized damage still occurs.
  • NSAID-Induced Ulcers:
    • NSAIDs exert their effects by inhibiting cyclooxygenase (COX) enzymes.
    • Systemic effect: Inhibition of COX-1 reduces the synthesis of cytoprotective prostaglandins (PGE2, PGI2), which are crucial for maintaining mucosal blood flow, bicarbonate secretion, and mucus production. This makes the mucosa vulnerable to acid.
    • Topical effect: NSAIDs are weak acids that can directly damage epithelial cells by ion trapping, leading to cellular injury and increased permeability.
  • Acid and Pepsin: Hydrochloric acid and pepsin are essential for digestion but become aggressive factors when mucosal defenses are impaired. High acid output, such as in ZES, can overwhelm even normal defenses.
• Risk Factors:
  • H. pylori infection: Primary cause.
  • NSAID/Aspirin (ASA) use: Especially chronic use, high doses, or concomitant use of corticosteroids or anticoagulants.
  • Smoking: Impairs mucosal healing, reduces prostaglandin production, increases gastric acid and pepsinogen secretion, and promotes H. pylori colonization.
  • Alcohol consumption: Direct mucosal irritant, but its independent role in ulcer formation is less clear than its role in delaying healing and promoting recurrence.
  • Stress: Psychological stress alone is not a primary cause of chronic PUD, but physiological stress in critically ill patients (e.g., sepsis, mechanical ventilation, burns, trauma, severe head injury) can lead to acute stress ulcers.
  • Corticosteroids: Increase the risk, especially when combined with NSAIDs.
  • Genetic predisposition: A family history of PUD may increase risk.
  • Diet: No strong evidence that specific foods cause PUD, but some foods may aggravate symptoms.
  • Comorbidities: Chronic kidney disease, chronic obstructive pulmonary disease (COPD), cirrhosis, cardiovascular disease (especially with antiplatelet therapy).
  • Other rare causes: Hypersecretory states (Zollinger-Ellison Syndrome), Crohn's disease, malignancy (gastric adenocarcinoma, lymphoma).
• Protective Factors:
  • Mucus layer: A gel-like layer rich in glycoproteins and phospholipids, trapping bicarbonate ions.
  • Bicarbonate secretion: Neutralizes acid in the mucus layer, creating a pH gradient.
  • Prostaglandins: Synthesized by COX-1, these compounds regulate mucosal blood flow, stimulate mucus and bicarbonate secretion, and promote epithelial cell turnover.
  • Mucosal blood flow: Maintains the integrity and reparative capacity of the mucosa by delivering oxygen, nutrients, and bicarbonate, and removing acid.
  • Epithelial regeneration: Rapid turnover of superficial epithelial cells, allowing repair of minor damage.
  • Tight junctions: Prevent back-diffusion of acid into the mucosa.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Epigastric Pain: The most common symptom, often described as burning, gnawing, aching, or "hunger-like." It is typically rhythmic and intermittent.
  • Pain-Food Relationship:
    • Duodenal Ulcer: Pain often occurs 2-5 hours after a meal, is frequently nocturnal (waking the patient), and is typically relieved by food or antacids.
    • Gastric Ulcer: Pain may be precipitated or worsened by food, occurring shortly after eating. Nausea, vomiting, and weight loss are more common.
• Early Signs:
  • Dyspepsia (indigestion)
  • Heartburn
  • Bloating
  • Nausea
  • Early satiety
• Advanced Signs: These suggest complications or more severe disease.
  • Weight loss: Due to fear of eating or malabsorption/malignancy.
  • Vomiting: Especially projectile vomiting, suggestive of gastric outlet obstruction.
  • Anemia symptoms: Pallor, fatigue, shortness of breath, palpitations, due to chronic blood loss.
  • Hematemesis (vomiting blood) or Melena (black, tarry stools): Indicative of upper GI bleeding.
  • Severe, sudden onset abdominal pain: Suggests perforation.
  • Back pain: May indicate posterior penetration of an ulcer into the pancreas.
• Atypical Presentations:
  • Silent Ulcers: Particularly common in the elderly or NSAID users, where symptoms may be minimal or absent until a complication (e.g., hemorrhage, perforation) occurs.
  • Chest pain: Ulcer pain can sometimes radiate to the chest, mimicking cardiac pain.
  • Generalized abdominal discomfort: Rather than focal epigastric pain.

Physical Examination

• Inspection:
  • Usually normal in uncomplicated PUD.
  • Pallor may be present if significant anemia from chronic blood loss.
  • Abdominal distention or visible peristalsis in cases of gastric outlet obstruction.
  • Signs of peritonitis (e.g., guarding, rigidity) if perforation.
• Palpation:
  • Mild to moderate epigastric tenderness is common.
  • Localized tenderness, guarding, and rebound tenderness are signs of peritonitis, indicating perforation.
  • A succussion splash may be elicited in gastric outlet obstruction (listening over the epigastrium while rocking the patient from side to side).
• Special Tests: None specific for uncomplicated PUD. Examination focuses on assessing for complications.

Diagnostic Approach

History Taking

• Key Questions:
  • Pain characteristics: Location (epigastric?), quality (burning, gnawing?), severity, duration, radiation, aggravating/alleviating factors (food, antacids).
  • Timing of pain: Relation to meals, nocturnal pain.
  • Associated symptoms: Nausea, vomiting, bloating, early satiety, dysphagia, odynophagia, weight loss.
  • Medication history: Detailed inquiry about NSAID, aspirin, corticosteroid, anticoagulant use.
  • H. pylori risk factors: History of infection, family history.
  • Lifestyle factors: Smoking, alcohol consumption.
  • Bleeding symptoms: Hematemesis, melena, hematochezia, dark stools, fatigue, dizziness (suggestive of anemia).
  • Complication symptoms: Sudden, severe abdominal pain (perforation), persistent vomiting (obstruction).
  • Past medical history: Prior PUD, GI bleeding, other chronic conditions.
• Red Flags: Symptoms that warrant urgent investigation (usually endoscopy) due to increased risk of malignancy or serious complications:
  • Age > 60 years with new-onset dyspepsia.
  • Dysphagia (difficulty swallowing) or Odynophagia (painful swallowing).
  • Recurrent or persistent vomiting.
  • Gastrointestinal bleeding (hematemesis, melena, hematochezia).
  • Unexplained weight loss (>5% body weight).
  • Iron deficiency anemia.
  • Palpable abdominal mass or lymphadenopathy.
  • Family history of upper GI cancer.
  • Jaundice.

Laboratory Tests

• First-Line:
  • H. pylori testing: Crucial for all patients presenting with PUD or dyspepsia.
    • Urea Breath Test (UBT): High sensitivity (90-96%) and specificity (88-98%). Measures H. pylori urease activity. Requires patient to be off PPIs for ≥1-2 weeks and antibiotics/bismuth for ≥4 weeks to avoid false negatives.
    • Stool Antigen Test (SAT): High sensitivity (94-98%) and specificity (90-95%). Detects H. pylori antigens in stool. Similar pre-test medication requirements as UBT.
    • Serology: Detects antibodies to H. pylori. Useful for initial diagnosis, especially if recent PPI/antibiotic use. However, it cannot differentiate active from past infection and remains positive for a long time after eradication, so it is not suitable for confirming eradication.
  • Complete Blood Count (CBC): To check for anemia (microcytic hypochromic anemia suggests chronic blood loss).
  • Electrolytes: May be deranged in patients with vomiting or severe bleeding.
• Confirmatory:
  • Upper Endoscopy with Biopsy: This is the gold standard for diagnosing PUD.
    • Allows direct visualization of the ulcer, its size, location, and characteristics (e.g., depth, signs of bleeding).
    • Biopsies can be taken from the ulcer edge and base (especially for gastric ulcers) to rule out malignancy and for rapid urease test (CLO test) or histopathology for H. pylori detection.
    • Biopsies should also be taken from the gastric antrum and body for H. pylori and to assess for gastritis or atrophy.
• Monitoring:
  • Repeat H. pylori testing: (UBT or SAT) 4 weeks or more after completion of eradication therapy to confirm successful eradication.
  • Repeat Endoscopy:
    • For gastric ulcers: Recommended 6-12 weeks after initial diagnosis and treatment to confirm healing and exclude underlying malignancy, regardless of initial biopsy results.
    • For duodenal ulcers: Generally not required if symptoms resolve and H. pylori is eradicated, as malignancy is extremely rare.
  • CBC: To monitor resolution of anemia if present.

Imaging

• Recommended:
  • Upper Endoscopy (Esophagogastroduodenoscopy - EGD): As discussed, it is the primary diagnostic and therapeutic modality.
• Advanced:
  • Computed Tomography (CT) Scan of Abdomen and Pelvis: Not a primary diagnostic tool for uncomplicated PUD, but invaluable in evaluating complications such as:
    • Perforation: Free air under the diaphragm, extraluminal air, localized fluid collections.
    • Penetration: Signs of inflammation in adjacent organs (e.g., pancreas, liver).
    • Gastric outlet obstruction: Gastric distention.
    • To rule out other causes of abdominal pain or to assess for gastrinoma in ZES.
  • Barium Upper Gastrointestinal (GI) Series: Less commonly used since the advent of endoscopy. Can demonstrate ulcer craters, deformities, or gastric outlet obstruction. However, it cannot reliably differentiate benign from malignant ulcers, cannot biopsy, and has lower sensitivity than endoscopy. May be considered if endoscopy is contraindicated or refused.

Management

Acute Management

This section primarily addresses acute complications of PUD. For uncomplicated PUD, acute management involves initiating acid suppression. - Immediate (for severe GI bleeding or suspected perforation): * Resuscitation: Two large-bore intravenous (IV) lines. Fluid resuscitation with crystalloids (e.g., normal saline or lactated Ringer's). * Blood products: Transfuse packed red blood cells as needed based on hemoglobin levels and signs of hypovolemia (e.g., target Hb >7 g/dL, or >8 g/dL in patients with cardiovascular disease). Platelets or fresh frozen plasma for coagulopathy. * Airway management: Protect airway in patients with significant hematemesis or altered mental status. * Nasogastric tube: May be inserted for lavage in severe upper GI bleed, though its routine use is debated. - Stabilization: * Pharmacological: * Proton Pump Inhibitor (PPI) IV infusion: High-dose IV PPI (e.g., pantoprazole 80 mg IV bolus, then 8 mg/hr continuous infusion for 72 hours) for patients with active upper GI bleeding, especially post-endoscopic therapy, to maintain intragastric pH > 6 and reduce rebleeding risk. * Correction of coagulopathy: Reverse anticoagulation or antiplatelet agents if possible and safe, considering the risks and benefits. * Endoscopic therapy: Performed emergently (within 12-24 hours) for active bleeding ulcers to achieve hemostasis (e.g., injection of epinephrine, thermal coagulation, hemoclip placement). - Emergency: * Surgical Consultation: Essential for patients with: * Perforation: Surgical repair (e.g., patch closure with omentum, Graham patch) is indicated for most perforations. * Uncontrolled Hemorrhage: If endoscopic methods fail to achieve hemostasis despite repeated attempts, or if the patient remains hemodynamically unstable. * Gastric Outlet Obstruction: If refractory to endoscopic dilation or prolonged medical therapy. * Penetration: If leading to intractable pain or abscess formation.

Chronic Management

• Pharmacological:
  • H. pylori Eradication Therapy: This is the cornerstone of management for H. pylori-associated PUD to prevent recurrence and complications. Multiple regimens exist, typically for 10-14 days.
    • First-Line Options:
      • Bismuth Quadruple Therapy: PPI (standard dose BID) + Bismuth subsalicylate/subcitrate (120-300 mg QID) + Metronidazole (250-500 mg QID) + Tetracycline (500 mg QID). Duration: 10-14 days. This is often preferred in areas with high clarithromycin resistance or as initial therapy.
      • Concomitant Therapy: PPI (standard dose BID) + Amoxicillin (1g BID) + Clarithromycin (500 mg BID) + Metronidazole (500 mg BID). Duration: 10-14 days.
      • Standard Triple Therapy: PPI (standard dose BID) + Clarithromycin (500 mg BID) + Amoxicillin (1g BID) or Metronidazole (500 mg BID). Duration: 10-14 days. Note: Use with caution due to increasing clarithromycin resistance (<15% resistance rate is acceptable).
    • Second-Line (Salvage) Therapy: If first-line fails, consider:
      • Levofloxacin-based triple therapy (PPI, amoxicillin, levofloxacin).
      • Bismuth quadruple therapy (if not used first-line).
      • Tailored therapy based on susceptibility testing (if available).
  • Acid Suppression Therapy (for NSAID-induced PUD or after H. pylori eradication):
    • Proton Pump Inhibitors (PPIs): Most potent acid suppressants. Examples: Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, Rabeprazole.
      • Dosing: Standard dose once daily for 4-8 weeks to promote healing (e.g., Omeprazole 20 mg daily, Lansoprazole 30 mg daily). For NSAID-induced ulcers, often requires 8-12 weeks.
      • Mechanism: Irreversibly inhibit the H+/K+-ATPase proton pump in parietal cells, reducing gastric acid secretion.
    • H2-Receptor Antagonists (H2RAs): Less potent than PPIs, but effective. Examples: Famotidine (20-40 mg BID).
      • Mechanism: Block histamine H2 receptors on parietal cells, reducing acid secretion. Often used for maintenance or mild symptoms.
  • Prophylaxis for NSAID-Induced Ulcers:
    • For high-risk patients who must continue NSAIDs: Long-term PPI therapy is recommended (e.g., Omeprazole 20 mg daily).
    • High-risk factors: History of PUD/GI bleeding, age >60-65 years, concomitant use of corticosteroids, anticoagulants, or antiplatelets, multiple comorbidities.
    • Alternative: Misoprostol (a prostaglandin analog, 200 mcg QID), but often limited by side effects (diarrhea, abdominal cramping) and contraindication in pregnancy.
• Non-pharmacological:
  • Avoid NSAIDs and Aspirin: If possible, discontinue or reduce dose. If ASA is for cardiovascular protection, discuss risks/benefits with the patient, often requiring concomitant PPI.
  • Smoking cessation: Promotes ulcer healing and reduces recurrence.
  • Alcohol moderation: High intake can delay healing.
  • Dietary modifications: While no specific diet cures ulcers, avoiding trigger foods (e.g., spicy foods, caffeine, acidic foods) that exacerbate symptoms is reasonable for individual patients.
  • Stress reduction: Though not a direct cause, stress can worsen symptoms.
• Monitoring:
  • Symptom resolution: Clinical improvement is a primary indicator of successful treatment.
  • H. pylori eradication confirmation: Urea Breath Test or Stool Antigen Test 4 weeks post-treatment is mandatory after H. pylori-associated PUD.
  • Repeat Endoscopy: For gastric ulcers, repeat EGD 6-12 weeks after treatment is essential to confirm healing and exclude malignancy. Less commonly needed for duodenal ulcers.

Treatment Algorithms

• First-Line (Initial Diagnosis of PUD):
  1. Stop NSAIDs/ASA: If they are the suspected cause.
  2. Test for H. pylori:
     • If H. pylori positive: Initiate H. pylori eradication therapy for 10-14 days. Follow with PPI (standard dose daily) for an additional 4-7 weeks to ensure ulcer healing.
     • If H. pylori negative AND NSAID/ASA use: Initiate PPI therapy for 8-12 weeks. If NSAID/ASA cannot be stopped, continue long-term PPI.
     • If H. pylori negative AND no NSAID/ASA use (or other obvious cause): Initiate PPI for 4-8 weeks. Consider workup for less common causes (e.g., ZES, Crohn's, malignancy; especially if gastric ulcer).
  3. Gastric Ulcers: Always biopsy and schedule repeat endoscopy 6-12 weeks after treatment to confirm healing and rule out malignancy.
• Second-Line (Failed H. pylori Eradication):
  1. Confirm adherence: Ensure patient completed the first-line regimen as prescribed.
  2. Test for H. pylori eradication failure: Use UBT or SAT, ensuring off PPI for 1-2 weeks and antibiotics/bismuth for 4 weeks.
  3. Initiate second-line H. pylori regimen: Choose a different antibiotic combination (e.g., if triple therapy failed, use bismuth quadruple therapy or levofloxacin-based therapy). Duration typically 10-14 days.
• Refractory Cases:
  • Refer to a Gastroenterologist: For expert management.
  • Re-evaluate diagnosis: Rule out other causes of ulcers (e.g., ZES, Crohn's, viral ulcers, malignancy, pill-induced injury, ischemia).
  • Assess drug resistance: Perform endoscopic biopsies for H. pylori culture and antibiotic susceptibility testing, if available.
  • Consider dose/duration adjustment: Higher dose or prolonged duration of PPI therapy.
  • Surgical intervention: Rarely required for truly refractory benign ulcers, but may be considered for severe complications despite optimal medical management.

Complications

• Common:
  • Gastrointestinal Bleeding: The most frequent and potentially life-threatening complication, occurring in 10-20% of ulcer patients. Presents as hematemesis, melena, or hematochezia. Can lead to anemia, hypovolemic shock.

• Serious:

  • Perforation: Occurs when the ulcer erodes through the entire gastric or duodenal wall, leading to leakage of GI contents into the peritoneal cavity and peritonitis. Characterized by sudden, severe, diffuse abdominal pain, guarding, rigidity, and rebound tenderness. A surgical emergency.
  • Gastric Outlet Obstruction (GOO): Occurs due to inflammation, edema, spasm, or scarring (fibrotic stricture) at the pylorus or duodenal bulb. Symptoms include early satiety, nausea, persistent postprandial vomiting (often undigested food), and weight loss.
  • Penetration: The ulcer erodes into an adjacent organ (e.g., pancreas, liver, biliary tree). Pain may radiate to the back (pancreatic involvement) or be more severe and constant.

• Long-term:

  • Recurrence: If H. pylori is not eradicated or NSAIDs are continued, ulcers are highly likely to recur.
  • Increased risk of gastric cancer: Chronic H. pylori infection (especially with gastric ulcers) is a significant risk factor for gastric adenocarcinoma and MALT lymphoma. Eradication of H. pylori reduces this risk.

Prognosis

• Factors:
  • Etiology: Prognosis is generally excellent with successful H. pylori eradication and cessation of NSAIDs.
  • Complications: Presence of complications (bleeding, perforation, obstruction) significantly worsens prognosis and increases morbidity and mortality.
  • Comorbidities: Underlying health conditions, especially cardiovascular disease, renal failure, or liver disease, can complicate management and worsen outcomes.
  • Patient adherence: Adherence to medication regimens (especially H. pylori eradication) and lifestyle modifications is crucial.
  • Smoking and alcohol: Continued smoking and heavy alcohol use negatively impact healing and increase recurrence rates.
• Survival:
  • For uncomplicated PUD, the prognosis is excellent with appropriate treatment.
  • Mortality from bleeding ulcers is around 5-10%, but can be higher in the elderly or those with severe comorbidities.
  • Mortality from perforated ulcers is substantial, ranging from 10-30%, depending on patient age, comorbidities, and time to surgery.
• Quality of Life:
  • Successful treatment leads to significant improvement in symptoms and overall quality of life.
  • Chronic, recurrent PUD or complications can severely impair daily activities and well-being.

Prevention

• Primary: Aimed at preventing the initial occurrence of PUD.
  • Avoid unnecessary NSAID/ASA use: Counsel patients on judicious use of NSAIDs. Consider alternative pain relief strategies.
  • Prophylactic acid suppression in high-risk NSAID users: For patients requiring chronic NSAIDs and having risk factors for PUD (e.g., history of PUD/bleeding, age >60-65, concomitant corticosteroids/anticoagulants/antiplatelets), co-prescription of a PPI (e.g., Omeprazole 20 mg daily) or misoprostol is recommended.
  • Selective COX-2 inhibitors (e.g., celecoxib): May be considered for high-risk patients requiring NSAIDs due to lower GI toxicity, but still carry risks, especially with concomitant ASA, and higher cardiovascular risk.
  • Avoid smoking and excessive alcohol: Counsel patients on cessation or moderation.
  • H. pylori screening and eradication: Population-based screening for H. pylori is not routinely recommended, but a "test-and-treat" strategy for symptomatic dyspepsia without alarm features is a primary preventive measure.
• Secondary: Early detection and intervention to prevent progression or recurrence.
  • Test and Treat H. pylori: For all patients with confirmed PUD, regardless of symptoms, test for H. pylori and eradicate if positive.
  • Close monitoring of gastric ulcers: Repeat endoscopy for gastric ulcers to confirm healing and exclude malignancy.
• Tertiary: Preventing complications in patients with established PUD or high-risk factors.
  • Long-term PPI therapy: For patients with a history of complicated PUD (e.g., bleeding, perforation), especially if they must continue NSAIDs/ASA.
  • Continue H. pylori eradication confirmation: Re-test 4 weeks after completion of eradication therapy.

Special Populations

• Pediatric:
  • Etiology: Less common than in adults. H. pylori and NSAID use (including low-dose aspirin) are common causes. Stress ulcers can occur in critically ill children.
  • Symptoms: May be less typical, often presenting as recurrent abdominal pain, nausea, vomiting, or poor feeding.
  • Diagnosis: Upper endoscopy is the gold standard. H. pylori testing (UBT, SAT, biopsy) is also crucial.
  • Management: PPIs are effective and generally safe. H. pylori eradication regimens are similar to adults but with weight-adjusted dosages. Bismuth quadruple therapy is usually avoided due to Reye's syndrome risk with bismuth subsalicylate in children with viral infections.
• Geriatric:
  • Incidence: Higher incidence of PUD, especially NSAID-induced, and increased risk of complications.
  • Presentation: Often present with "silent" ulcers (minimal or no pain) until a complication (bleeding, perforation) occurs. Nonspecific symptoms like fatigue, weakness, or mental status changes may be the first indication.
  • Management: Careful review of medication list for NSAIDs/ASA. High suspicion for complications. PPIs are generally safe and effective, but monitor for potential long-term side effects (e.g., C. difficile infection, osteoporosis).
  • Prognosis: Higher mortality rate with complications compared to younger adults.
• Pregnancy:
  • Diagnosis: Endoscopy is generally safe if indicated but deferred if possible. H. pylori testing (UBT, SAT) is preferred over serology.
  • Management:
    • Acid suppression: H2RAs (famotidine, ranitidine) or PPIs (omeprazole, lansoprazole, pantoprazole) are generally considered safe (Category B).
    • H. pylori eradication: Typically delayed until after pregnancy if possible, especially in asymptomatic cases. If treatment is necessary, amoxicillin and metronidazole are considered relatively safe. Clarithromycin (Category C) should be used with caution. Tetracycline and bismuth are contraindicated.
  • NSAIDs: Avoid NSAIDs, especially in the third trimester due to risk of premature ductus arteriosus closure.
• Comorbidities:
  • Cardiovascular Disease: Patients often require antiplatelet (ASA, clopidogrel) or anticoagulant therapy, significantly increasing the risk of GI bleeding from ulcers. Co-prescription of a PPI (e.g., omeprazole, pantoprazole) is strongly recommended for these patients, especially if they have a history of PUD or other GI bleeding risk factors. Note: Omeprazole and esomeprazole may have a minor interaction with clopidogrel, but clinical significance is debated; overall, PPI benefits in reducing GI bleed risk often outweigh this theoretical risk.
  • Chronic Kidney Disease/Liver Disease: Requires dose adjustments for certain medications (e.g., antibiotics, H2RAs). Increased bleeding risk in liver disease (coagulopathy, portal hypertension).
  • Critical Illness: High risk of stress ulcers. Prophylaxis with H2RAs or PPIs is often used in ICU settings for high-risk patients (e.g., mechanical ventilation >48h, coagulopathy, severe burns, head trauma, sepsis).

Clinical Pearls

• Diagnostic:
  • Always test for H. pylori: In all patients with active PUD or history of PUD, and in those with dyspepsia without alarm features.
  • Gastric ulcers need follow-up: Any gastric ulcer, even if initially appearing benign and biopsied, requires repeat endoscopy 6-12 weeks after treatment to confirm healing and exclude underlying malignancy. Duodenal ulcers rarely require follow-up endoscopy.
  • Consider NSAID/ASA use: Actively ask about all medications, including OTC, as NSAID use can be easily overlooked.
  • Red flags are key: Alarm symptoms should prompt urgent endoscopy.
• Treatment:
  • Adherence is crucial for H. pylori eradication: Emphasize the importance of completing the full course of antibiotics and PPI to patients.
  • Stop the offending agent: Discontinuation of NSAIDs/ASA is paramount for healing and preventing recurrence in NSAID-induced ulcers.
  • PPIs are generally safe for long-term use: But be mindful of potential (though rare) side effects, especially in high-risk patients (osteoporosis/fractures, C. difficile infection, hypomagnesemia, acute interstitial nephritis). Use the lowest effective dose for the shortest necessary duration.
  • Prophylaxis in high-risk NSAID users: Remember to co-prescribe a PPI for patients on chronic NSAIDs/ASA with risk factors for GI bleeding.
• Pitfalls:
  • Failure to test for H. pylori.
  • Inadequate duration or dose of H. pylori eradication therapy.
  • Failure to confirm H. pylori eradication after treatment.
  • Missing a gastric malignancy: By not performing biopsies or follow-up endoscopy for gastric ulcers.
  • Continuing NSAID/ASA without appropriate gastroprotection.
  • Prescribing empiric H. pylori treatment without confirmation, leading to antibiotic resistance or missed diagnoses.

Recent Updates

• Guidelines:
  • American College of Gastroenterology (ACG): Publishes guidelines on the management of H. pylori infection and dyspepsia, emphasizing a "test-and-treat" approach.
  • European Helicobacter and Microbiota Study Group (EHMSG): The Maastricht Consensus Reports provide comprehensive, regularly updated guidelines on H. pylori management based on global evidence.
  • Asia-Pacific Consensus: Provides region-specific guidelines relevant to areas with high H. pylori prevalence and resistance patterns.
• Evidence:
  • Increasing Clarithromycin Resistance: Global rates of clarithromycin resistance have been rising, significantly impacting the efficacy of standard triple therapy for H. pylori. This has led to recommendations for bismuth quadruple therapy or concomitant therapy as first-line in many regions, especially where clarithromycin resistance rates exceed 15-20%.
  • Role of Probiotics: Some evidence suggests that certain probiotic strains (e.g., Lactobacillus and Bifidobacterium) co-administered with H. pylori eradication therapy may improve eradication rates and reduce antibiotic-related side effects, although not universally recommended as standard practice.
  • Long-term PPI use: Ongoing debate and research regarding the long-term safety profile of PPIs, with studies exploring associations with kidney disease, dementia, and other conditions, though causality remains largely unproven and absolute risks are generally low. The consensus remains to use PPIs for appropriate indications at the lowest effective dose for the shortest duration.
• Controversies:
  • Optimal First-Line H. pylori Regimen: The best first-line therapy for H. pylori eradication varies significantly by geographic region due to differing antibiotic resistance patterns. There is no single "best" regimen universally. Local resistance data should ideally guide empiric therapy choices.
  • Empiric PPI vs. Test-and-Treat: For uninvestigated dyspepsia without alarm features, a "test-and-treat" strategy for H. pylori is preferred, but empiric PPI use is still common in some practices.
  • Risk vs. Benefit of Long-term PPI in High-Risk Patients: Balancing the proven benefits of PPIs in preventing GI bleeding against the theoretical or low absolute risks of long-term adverse events.

Key References

• Guidelines:
  • Chey, W. D., et al. (2017). ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. The American Journal of Gastroenterology, 112(2), 212-239.
  • Malfertheiner, P., et al. (2017). Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut, 66(1), 6-30.
  • Lanza, F. L., et al. (2009). American College of Gastroenterology Guideline: Prevention of NSAID-Related Ulcer Complications. The American Journal of Gastroenterology, 104(3), 728-738.
• Studies:
  • Graham, D. Y., et al. (1992). Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Annals of Internal Medicine, 116(9), 705-708. (Landmark study on H. pylori and ulcer recurrence).
  • Chan, F. K. L., et al. (2001). Clopidogrel versus aspirin and celecoxib for the prevention of recurrent ulcer bleeding. The New England Journal of Medicine, 344(24), 1795-1801. (Study on NSAIDs, antiplatelets, and ulcer prevention).
• Reviews:
  • Kavitt, R. T., et al. (2016). Diagnosis and treatment of peptic ulcer disease. Clinical Gastroenterology and Hepatology, 14(11), 1492-1502.
  • Laine, L., et al. (2016). NSAIDs and gastrointestinal damage: a review of current and future strategies for prevention. Alimentary Pharmacology & Therapeutics, 44(2), 147-160.